1 / 17

Testicular cancer: current views

Testicular cancer: current views. Dr. M. Mangala MD (Kin); FRCS (Ireland); MMed (Wits); FCS (SA) Urology 38 th BMA CONGRESS. Background. 1% and 1.5% male neoplasms 5% all urological tumors Prevalence 2-3/100000 In the 15-34 y.o 62/100000 5% cases bilateral

hyatt-whitaker
Télécharger la présentation

Testicular cancer: current views

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Testicular cancer: current views Dr. M. Mangala MD (Kin); FRCS (Ireland); MMed (Wits); FCS (SA) Urology 38th BMA CONGRESS

  2. Background • 1% and 1.5% male neoplasms • 5% all urological tumors • Prevalence 2-3/100000 • In the 15-34 y.o 62/100000 • 5% cases bilateral • Duplication of the short arm of X12 • Isochromosome 12p or I(12p)

  3. Diagnosis • Scrotal US • Sensitivity 100% • MRI • Sensitivity 100% and Specificity 95-100% • High cost: not justified

  4. Diagnosis • Serum tumour markers • AFP produced by yolk sac: T1/2 5-7 days • hCG expression of trophoblasts: T1/2 2-3 days • B subunit specific • LDH marker of tissue destruction (bulk) • Inguinal exploration and orchidectomy • Radical orchidectomy

  5. Diagnosis • False AFP elevation • Cancers: Hepatobiliary, pancreatic, gastric, lung • Benign: Liver conditions • False elevation hCG • Cancers: Lung, hepatobiliary, gastric, pancreatic, multiple myeloma

  6. Tumour marker by histological type

  7. On orchidectomy • Organ-sparing surgery • In suspicion of a benign-lesion • In synchronous, bilateral testicular tumours • In metachronous, contralateral tumours • In a tumour in a solitary testis The tumour should be less than 30% of the testicular volume.

  8. Staging and clinical classification • To determine the presence of metastatic or occult disease • Tumour markers • Nodal pathway screened • Visceral metastasis excluded • Abdominal, supra-clavicular nodes, liver • Status of mediastinal and lung metastasis • Status of brain and bone if suspicion

  9. Staging and clinical classification • Abdominal, pulmonary, extra-pulmonary, mediastinal node assessed by CT • Supraclavicular nodes. PE and CT • Retroperitoneal nodes CT • MRI as CT but cost limit its use. • FDG-PET: F/U of Residual mass seminoma post CRx • WW or active treatment?

  10. Classification • TNM • pTX: Primary tumour can’t be assessed • pT0 : No evidence of primary tumour • pTis: Intratubular germ cell neoplasia • pT1: Tumour limited to testis and epidydimis without vascular/lymphatic invasion _ pT2: same with invasion

  11. Classification • TNM • pT3: Invasion of the spermatic cord • pT4: Tumour invades scrotum with or without vascular/lymphatic invasion • Serum markers • Sx, S0, S1, S2, S3 according to level of LDH, hCG, AFP.

  12. Classification • Stage I: Confined to the testis • Stage IA: pT1, N0, M0, S0 • Stage IB: pT2, N0, M0, S0 • Stage IS: pT/Tx, N0, M0, S1-3 • Stage II: Retroperitoneal involvement • IIA nodes < 2cm, IIB nodes > 2cm • Stage III: Nodes visceral or supradiaphragmatic

  13. Treatment: Seminoma • Low-stage: I,IIA • Surgery, DXT to retroperitoneum • High-stage: IIB, III (Bulky and elevated AFP) • Primary CRx (Sensitivity to platinum) • Residual mass Mx controversial

  14. Treatment: NSGCT • Low-stage • RPLND • Surveillance • Tumour within tunica albuginea • Normal tumour markers after orchidectomy • No vascular invasion • No sign of disease on imaging • Reliable patient

  15. Treatment: NSGCT • Surveillance • Monthly visit 1/12 for 2 years • Bimonthly third year • Tumour markers each visit • CXR, CT Scan q 3/12

  16. Treatment: NSGCT • High-stage • Primary CRx • Tumour marker stable • If residual mass excision • Tumour marker raised • Salvage CRx

  17. Follow-up • Labour intensive • Don’t forget to palpate • Remaining testis • Abdomen • Lymph node area

More Related